Back to Grants
FEDERAL
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
This grant funds early stage testing of pharmacologic or neuromodulatory device-based interventions aimed at treating mental disorders.
About this program
The grant supports research focused on the early stage testing of innovative pharmacologic or neuromodulatory devices designed to address mental health disorders. It is intended for researchers and institutions engaged in clinical trials that explore new treatment modalities for mental health conditions. The funding will facilitate the development and evaluation of these interventions, contributing to the advancement of mental health treatment options.
Eligibility
Eligible applicants include academic institutions, nonprofit organizations, and other entities involved in clinical research.